UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
-
31st Dec 17 Source: CRO
- €163 million turnover
-
€12.2 million
profit - 1 employees
- 10 more years available »
Ranking
By Turnover
(€36.9 million)- 755th in Top Companies
- 88th in Health
- 75th in Pharma
By Employees
(1)- 986th in Top Companies
- 94th in Health
- 81st in Pharma
-
- 1
- €36.9 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 2:29pm Covid-19 vaccine sprint as Pfizer-BioNTech, Moderna seek emergency EU approval
- 1:31pm Central Bank offers to assist with coronavirus contact tracing
- 1:01pm Judge rejects examinership application for Ina’s Kitchen Desserts
- 10:27am OECD sees global economy turning the corner on coronavirus crisis
- 10:17am Debenhams set to close all stores after starting liquidation process